Abstract:OBJECTIVE:To prepare AS1411 targeted nano-ultrasonic contrast agent with liquid core, and to evaluate its ability for ultrasonic contrast enhancement and targeting MCF-7 cell in vitro. Methods: The modified solvent evaporation, self-synthesized membrane material and perfluorobrominane (PFOB) was used to form nano-ultrasonic contrast agent with PFOB core (nanoparticles, NP); then N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) catalysis was used to connect AS1411 to the surface of NP to prepare NP-AS1411. The transmission electron microscopy was chosen to check the morphology of NP-AS1411. The size, surface charge, encapsulation efficiency, biocompatibility, the contrast grey value and the stability of NP-AS1411 and NP were compared. Whether AS411 was attached to the surface of NP was checked by gel electrophoresis. Fluorescence microscopy and flow cytometry were performed to examine the targeting ability of AS1411. Results: NP-AS1411 was a shell-nuclear structure under the electron microscope. Its size was at (245.4±16.5) nm, which was larger than that of NP (P=0.05). There was no significant difference in surface charge and encapsulation efficiency between NP-AS1411 and NP (P>0.05). In the MTT experiment, the cell viability decreased significantly at high concentration of NP-AS411 (25 mg/mL) after incubation for 24 h compared with the control group (0 mg/mL ) (P<0.05). The contrast gray value of NP-AS1411 was at 86.1+ 6.7, which was significantly higher than that of deionized water (P<0.05), and equivalent to that of NP (P>0.05). The contrast grey value of AS1411-NP was 80.1±9.2 after keeping at room temperature for 24 h, which showed no obviously change comparing with that before the treatment (P>0.05). The size of NP-AS1411didn't change too (P>0.05). The results of gel electrophoresis demonstrated that the AS1411 connecting to the surface of NP was the most when the molar ratio of NP:AS1411 was at 40:1. Flow cytometry analysis confirmed that NP and NP-AS1411 were combined with MCF-7 cells separately but the fluorescence produced by the combination of NP-AS1411 and MCF-7 was more intense. Conclusion: The modified solvent evaporation and EDC/NHS catalysis could successfully prepare ultrasound contrast agents with aptamer-conjugated nanoparticles with liquid core. The targeted ultrasonic contrast agents with liquid core possess good ultrasonic contrast enhancement ability in vitro, stability and specificity as well.

Preparation of Asialoglycoprotein Receptor-Mediated Hepatic Targeting Nano- Lipid Ultrasound Contrast Agent and Its Ultrasound Imaging in Vitro

Preparation and in Vitro-Targeted Study of Liquid Perfluorocarbons-Filled Nanocapsules Ultrasound Contrast Agent

Reaserch on nanoscale liquid fluorocarbon poly lactic-co-glycolic acid ultrasound microcapsule for the cambination of ultrasound imaging and photothermal therapy

Experimental study on preparation and targeting research in vitro of targeted nanoparticle ultrasound contrast agent carrying cRGD

Preparation of Folate Receptor-Targeted Contrast Agent with Liquid Fluorocarbon Nanoparticles Encapsuled in Lipid Membrane and Its Targeting Performance Study in Vitro

Construction of a Visualized Liver-Targeting Sirna Delivery System

[Development and Evaluation of Ultrasound Contrast Agents with AS1411-conjugated Nanoparticles with Liquid Core].

Preliminary experimental study on evaluation of liver injury by ultrasonic targeting imaging

Characteristics and Enhancement Effect of A Self-made Nano-lipid Ultrasound-enhanced Contrast:In Vitro and in Vivo Experimental Study

Preparation and Experimental Study in Vitro on Nanoscale Lipid Ultrasound Contrast Agent Targeting to HER2

High-fidelity Imaging of Fatty Liver in Vivo with a Fluorescent and Photoacoustic Dual-Mode Probe by Taking Advantage of the Liver “first Pass Effect”

SPIO-loaded Nanostructured Lipid Carriers As Liver-Targeted Molecular T2-weighted MRI Contrast Agent.

Preparation and Evaluation of Neovessel-targeted Paramagnetic PEGylated Liposome

A photothermal ultrasound contrast agent: preparation, in vitro and in vivo investigation of gold nanoshelled poly(lactide-co-glycolic acid) nanoparticles

A Novel Nanoscale Phase-Change Contrast Agent Evaluates the Hepatic Fibrosis Through Targeting Hepatic Stellate Cell Platelet-Derived Factor Beta Receptor by Ultrasound in Vitro

Preparation of Hepatic Targeting Predrug Galactosyi-Human Serum Albumin 5-Fluorouracil and Its Targeting Effect

Preparation and Evaluation of Glycyrrhetinic Acid-Modified and Honokiol-Loaded Acoustic Nanodroplets for Targeted Tumor Imaging and Therapy with Low-Boiling-point Phase-Change Perfluorocarbon.

Preparation and Characterization of Novel Perfluorooctyl Bromide Nanoparticle As Ultrasound Contrast Agent Via Layer-by-Layer Self-Assembly for Folate-Receptor-Mediated Tumor Imaging.

Preparation of anti-HER-2 antibody PLGA polymer nano- ultrasound contrast agent In vitro targeting experiment

Preparation of Alg-LacPLLNP and its liver targeting research

Preparation of Molecular Polymer Ultrasound Contrast Agents with Liquid Perfluorocarbons and in Vitro Experiment